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Introduction 1
Statins are inhibitors of the enzyme 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase, which converts 2 HMG-CoA into mevalonate, the rate-limiting step in the cholesterol biosynthesis [1] [2] [3] . Several clinical trials 3 have shown that statins can significantly reduce plasma low density lipoprotein (LDL) cholesterol and the risk 4 of cardiovascular events and mortality in patients with or without coronary artery disease [2, 4, 5] . Statins reduce 5 intracellular cholesterol, leading to increased expression of LDL receptor (LDLR) [6] and enhanced clearance 6 of LDL and its precursors [1, 6] . However, inhibiting mevalonate synthesis is not only blocking the formation 7 of cholesterol, leading to pleiotropic effects [6] . Statins have been associated with inhibition of cell 8 proliferation, enhanced apoptosis, anti-inflammatory properties, improved endothelial function and 9 modulation of angiogenesis [7, 8] . 10 Exact molecular mechanisms of those LDL-cholesterol independent effects are not yet fully understood. Most 11 of the earlier studies investigating changes at the transcriptional level have been based on microarray analyses 12 [9]. To our knowledge this is the first study where RNA-sequencing is used to achieve unbiased and more 13 sensitive detection of transcripts regulated by rosuvastatin (Ros) treatment in mice. 14 In the liver lipids are stored in lipid droplets (LD) [10] , where the composition of lipids and proteins is 15 determining the fate of a LD [10] . It is assumed that statins can reduce lipid accumulation in the liver, but the 16 underlying mechanisms are not yet fully understood [11] . Perilipins, a family consisting of five members 17 (Perilipins 1-5 (Plin1-5)), are the largest family of proteins in LD and each perilipin has a specific role in 18 biogenesis, stabilization and degradation of LDs [10] . However, not much is known about the role of perilipins 19 in hepatocytes [10] . 20 Inflammation plays a key role in atherosclerosis and it increases the risk of cardiovascular diseases [12] . C-21 reactive protein (CRP), a classical acute phase plasma protein induced by inflammation and tissue damage, is 22 an emerging biomarker for the risk of cardiovascular diseases and cardiovascular death [13, 14] . Several large-23 scale randomized, controlled trials have shown that statins can reduce CRP in addition to their cholesterol 24 lowering effects [13] . 25
In this study we used mice overexpressing insulin-like growth factor 2 (IGF-II) with LDLR deficiency (LDLR -26 Teklad) or a western diet (Harlan Teklad) for two months prior to treatment. At 4 months of age, the animals 5 were subdivided into two groups per diet and treatment groups were given rosuvastatin (Crestor®, 6 AstraZeneca) mixed in their food for twelve weeks according to previously tested protocol [18] . Due to 7 preferential intake of the regular chow diet (RCD) the treatment RCD contained 0.07mg/gDiet of rosuvastatin 8 (RCD-Ros) compared to the western diet (WD), where 0.1mg/gDiet of rosuvastatin (WD-Ros) was used. After 9 twelve weeks animals were sacrificed and samples were taken. All animal procedures were approved by the 10 
Echocardiography 1
Echocardiography measurements were performed at baseline and 6 and 12 weeks after the treatment, by using 2 Vevo2100 Ultrasound System (FUJIFILM Visual Sonics Inc.) using a high-frequency ultrasound probe 3 (MS400) operating at 18-38 MHs. Animals were anesthetized with isoflurane (Induction: 4.5% isoflurane, 4 450ml air, maintenance: 2% isoflurane, 200 ml air, Baxter International Inc.). Ejection fraction (EF), left 5 ventricular (LV) mass, LV volume, LV anterior wall (LVAW), LV posterior wall (LVPW) and LV internal 6 diameter (LVID) were measured from parasternal short axis M-mode. Three measurements in different 7 breathing cycles were acquired and EF was calculated by the Vevo program with the Teichholz formula. Mice were sacrificed 12 weeks after the treatment and the tissues were perfused with phosphate buffered saline 11 (Dulbecco's Phosphate Buffered Saline, D8537, Sigma Aldrich), followed by 4h fixation in 4% 12 paraformaldehyde in 7.5% sucrose. Samples were subsequently transferred to 15% sucrose and processed 13 within the following days. stained sections at the branching point between ascending aorta and coronary artery. Lesion size was analyzed 18 as described above. Steatosis was quantified from hematoxylin-eosin stained liver sections with ImageJ Fiji 19 from five different sections at a magnification of 400x. To quantify liver fibrosis, the sections were stained 20 with Picro-Sirius Red (ab150681, Abcam) and quantified as above mentioned. All images were taken with 21 Nikon Eclipse Ni microscope with a Ds-Ri2 camera (Nikon Instruments Europe BV). 22 23 2.5. RNA-sequencing library preparation and data analysis 24 RNA-Seq libraries were prepared as described [20] , except that RNA was isolated from snap frozen livers by 25 using Trizol reagent (RNA/DNA/Protein Isolation Reagent, Molecular Research Center Inc) and ribosomal 7 RNA was removed by using RiboZero Gold kit (#MRZG12324, Illumina). Final libraries were amplified using 1 13-14 cycles and were sequenced for 50 cycles using Illumina HiSeq 2000 at EMBL Genomics Core Facility 2 (Heidelberg, Germany). Processing of sequencing reads was carried out as described [21] , except that data was 3 mapped to mouse genome (version mm9) using tophat v2.0.7 [22] . Differentially expressed genes were 4 identified by quantifying exonic reads with analyzeRepeats.pl tool included in HOMER 4.7 software followed 5 by edgeR analysis [23] thresholds of FDR < 0.05, reads per kb per million reads (RPKM) > 0.5 and fold change 6 2. Venn diagram was made using Venny2.1 program and gene ontology analysis was performed using GO 7 Enrichment Analysis [24-26]. 8
RNA-seq data access: 9
The RNA-seq data can be found under GEO accession number GSE111125 10 (Reviewers can access the data from link: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111125 11
Enter token ubatoeumdfqxjuv into the box) BioRad Laboratories Inc.). Membranes were blocked in 5% skim milk in TBS-Tween and incubated with the 21 following antibodies overnight: Plin4 (Everest Biotech, Ramona, USA), Plin5 (Thermo Fisher Scientific), 22
Trib2 (Cell Signalling Technologys), Trib3 (Thermo Fisher Scientific), pAkt, mTOR, pmTOR, Erk1/2 and 23 pErk1/2 (Cell Signalling Technologys) with corresponding secondary antibodies. Proteins were detected with 24
ChemiDoc XRS (BioRad) by using ECL-Plus kit (Pierce ECL Plus, Thermo Scientific). Stain-free gels were 25 UV activated for 2.5 min before blotting and total protein amount was measured with ChemiDox XRS before 1 ECL detection, specific bands were normalized to total protein using the ImageLab software (BioRad). Ros treatment did not modify glucose levels significantly when compared to control animals on the same diet. 4
Six weeks after the treatment, mice fed with RCD showed significantly lower values of HbA1c compared to 5 RCD-Ros fed mice. This difference, however, disappeared after 12 weeks of treatment. Animals fed with WD 6 did not show any significant changes in the HbA1c levels between control and Ros treated groups. By the end 7 of the study, RCD animals had similar weights as animals fed with WD ( While in RCD fed animals insulin levels increased significantly over time compared to baseline levels, insulin 5 levels decreased significantly in WD-Ros mice ( Figure 1A) . 6
To investigate the effect of Ros on glucose and insulin regulation in IGF-II/LDLR -/-ApoB 100/100 mice, IPGTT 7 and IPITT tests were performed at baseline and 6 and 12 weeks after the treatment. The area under the curve 8 (AUC) showed no changes irrespective of the diets or treatment (Figure 1 with Bonferroni post-test was used for Insulin level and AUC comparison. Insulin levels n=4-7/group, IPGTT 4 and IPITT n=5-11/group. 5
WD-Ros significantly reduced total cholesterol levels 6
To verify if cholesterol levels decline despite of the LDLR deficiency, total cholesterol was measured. We 7 could show that mice fed with WD-Ros showed significantly lower total cholesterol levels 12 weeks after the 8 treatment compared to baseline values and when comparing WD-Ros treated mice to WD control (Figure 2  1 B). Similar trends were seen when animals were fed with RCD and in triglyceride levels (Figure 2 A, C, D) . 2 We further investigated whether Ros was able to reduce atherosclerosis in LDLR -/-ApoB 100/100 mice. Lesion 3 areas in aortic sinuses and coronary arteries showed no significant reduction between control and Ros groups 4 (Figure 2 E, F) . These results indicate that lesions in mice fed WD are already quite progressed and cannot be 5 reduced within the treatment period. Values are shown as a mean ± SEM and statistical analysis was performed by using one-way ANOVA with 2 Bonferroni post-test for lipid measurements and Student´s t-test for lesion measurements. Plasma levels n=7-3 12/group, Aortic sinus lesion area and stenosis n=7-10/group. To analyze if Ros affects liver steatosis and fibrosis, hematoxylin-eosin and picro-sirius red stainings were 6 performed. We demonstrate that steatosis was significantly reduced, to a similar level as in RCD fed mice, in 7 animals fed with WD-Ros. No changes were seen in mice fed with RCD or RCD-Ros (Figure 3 A, D) . Similar 8 results were seen when LD sizes were investigated (Figure 3 B, D) . However, fibrotic area increased 9 significantly in animals treated with WD-Ros compared to control animals (Figure 3 C, D). RNA-seq was used to investigate the genome-wide transcriptional effects of Ros in the liver. In RCD-Ros fed 6 mice compared to control mice, expression of 19 genes was significantly changed, of which 16 genes were up-7 and three were down-regulated. In WD-Ros group, 216 genes were differentially regulated compared to WD 8 control animals. Of these 128 genes were down-and 88 were up-regulated (Table1S). Only eight genes were 9 differentially regulated independently of the diet (Fig.4 A) . The low number of affected genes together with 10 the volcano plots ( Fig. 4 D) emphasizes the specificity of statin treatment. Gene ontology studies revealed that 11 the commonly regulated genes mainly belong to cholesterol pathways. When mice were fed with RCD, mainly 12 genes involved in lipid metabolism were affected by Ros treatment. When animals were fed with WD, genes 13 involved in lipid metabolism and inflammation were differentially regulated upon Ros treatment ( Fig. 4 B and  14 
C). 15
The increased inflammatory state during WD could be verified by plasma analysis. As expected, plasma CRP 16 values were significantly increased in animals fed with WD compared to RCD. Furthermore, a significant 17 reduction in plasma CRP was observed in animals treated with WD-Ros compared to WD control animals. A 18 similar effect was seen in plasma Saa values. The increased levels of Saa during WD could be significantly 19 diminished by Ros treatment (Figure 4 E) . These results clearly emphasize the anti-inflammatory effects of 20
statins. 21
With RNA-seq we were able to identify two groups of genes, Plin and Tribbles (Trib) which are affected by 22 Ros treatment. It is known that Plin5 plays an important role in controlling lipolysis, the role of Plin4, in 23 contrast, is not very well understood [27] . Here we show that in Ros treated mice, Plin4 was downregulated 24 independently of the diet while Plin5 only showed a small decrease in WD-Ros. Investigation of the protein 25 level showed that Plin4 was increased in WD fed mice when compared to RCD. However, no difference 26 between control and Ros treated animals was seen (Figure 4 F) . Plin5 exhibited very low protein expression level in liver, which is in line with the sequencing data. When animals were treated with RCD-Ros a significant 1 increase in Plin5 was visible, but no difference, however, was seen in WD groups (Figure 4 F) . Trib proteins are signaling mainly through mitogen-activated protein kinase (Mapk) and Pi3k 12 (phosphoinositide 3-kinase) pathways [29] . Therefore, downstream signaling of Trib3 was studied in more 13 detail. No changes were seen in pAkt between placebo and Ros treated animals (Figure 5 A) . Thus, Trib3 14 downregulation did not affect phosphorylation of Akt. However, pmTOR was significantly increased in Ros mice, while mTOR levels did not differ (Figure 5 A, C and D). Thus, statin treatment might activate 16 phosphorylation of mTOR in mice fed with WD. Erk1/2 was increased with Ros treatment both during RCD 17 and WD but no changes in phosphorylation of Erk1/2 were detected ( Figure 5 D and E). To evaluate if Ros treatment influenced cardiac performance, echocardiography was performed at baseline and 8 6 and 12 weeks after the treatment. Ros treatment, however had no significant effect on the cardiac 9 performance, neither when animals were fed with RCD nor with WD (Table 2) . 
Discussion 1
This study was performed to investigate the specificity and molecular mechanisms of statin treatment in 2 hyperlipidemic prediabetic mice. Statin treatment can increase the risk of type 2 diabetes, especially in people 3 with impaired glucose metabolism [30, 31] . Hence, we closely monitored changes in glucose metabolism. In 4 this mouse model, Ros treatment did not affect glucose metabolism negatively. On the contrary, there was a 5 clear trend towards a better glucose tolerance in mice treated with WD-Ros compared to mice fed with WD. 6 LDLR -/-ApoB 100/100 is a commonly used mouse model for human familial hypercholesterolemia and 7 atherosclerosis [32] . Although the main mechanism of statins to lower cholesterol is via LDLR upregulation, 8 it has been shown that statins can reduce total cholesterol even if LDLR is absent or defective by decreasing 9
ApoB production [33,34]. Also, it has been shown that in patients with nonalcoholic steatohepatitis the 10 absolute rate of ApoB-100 synthesis is reduced [35] . These findings support the view that in animals lacking 11 LDLR, ApoB reduction is the main mechanism for the decrease in total cholesterol. 12 We showed that total plasma cholesterol levels were reduced with statin treatment, especially when animals 13 were fed WD. However, RNA-seq analysis did not reveal any specific mechanisms behind this reduction. No 14 changes were seen in RNA expression levels of lipoprotein receptors, such as Ldlr related protein 1 (Lrp), 15
Very low-density lipoprotein receptor (Vldlr) or Scavenger receptor class B 1 (Scarb1). Also, ApoB or 16 microsomal triglyceride transfer protein (Mtp) did not change significantly with Ros treatment. Although 17 animals fed with WD-Ros lost weight in the beginning of the study, at 12 weeks after the treatment, the weight 18 was not anymore significantly different and therefore not responsible for the changes in cholesterol levels. 19 Recently Pei Yu et al. [36] showed that in ApoE -/mice lacking Scarb1, Ros treatment reduced atherosclerosis 20 in aortic sinuses and coronary arteries without lowering total cholesterol levels. In our study, statin treatment 21 was not able to reduce aortic sinus lesions or coronary artery stenosis, showing that if lesions are already 22 advanced, their reduction is unlikely by statin treatment in animals lacking LDLR. In contrast to stenosis 23 progression, Ros was able to significantly reduce steatosis in livers of WD fed animals compared to control 24 treated mice. Additionally, liver LD decreased significantly in size. Surprisingly, animals fed with WD-Ros 25 showed increased levels of fibrosis in their livers which is in line with RNA-seq results where increased levels 26 of fibrotic genes such as collagen type 1 alpha 1 chain (Col1a1) were visible. However, Okada et al.[37] 27 showed that Ros inhibited liver fibrosis in a rat model of high-fat and high-cholesterol diet. In more detail, 28 they could show that transforming growth factor-β (Tgf-β), connective tissue growth factor (Ctgf) and Col1a1 1 mRNA levels were downregulated in the liver after Ros treatment. In contrary, our results show that Tgf-β and 2 Ctgf expression levels were not changed but Col1a1 was significantly upregulated. However, differences in 3 species and animal models may explain these different findings. 4
To investigate transcriptional changes of Ros treatment, RNA-seq from the livers was performed. Only 19 5 genes in the RCD group and 216 genes in the WD group were altered with WD-Ros compared to control 6 animals, which supports the specificity of Ros at the molecular level. As shown by Wang et al. [38] high fat 7
diet has a large impact on hepatic gene regulation. They identified 160 genes which were differentially 8 expressed when high fat diet was compared to a regular chow diet. Twenty-five of those genes were found to 9 be differentially regulated also in our study. These include genes affecting inflammatory and oxidative stress 10 responses, such as C-X-C motif chemokine ligand 1 (Cxcl1) and Saa3 which were upregulated during WD in showed that reducing inflammation decreased the risk of cardiovascular events independently of lipid-levels 20
[40]. In this study, we could show that CRP levels decreased significantly in mice fed with WD-Ros compared 21 to WD diet control mice. In addition to CRP also Saa has been shown to be a good predictor for cardiovascular 22 events [41]. Similar to CRP, hepatic Saa increases as a response to inflammation and statin treatment can lower 23 Saa plasma levels [41, 42] . In our study, both Saa1 and 2 RNA expression in the liver was significantly 24 downregulated with WD-Ros. Further, we could confirm that Saa1 plasma levels were significantly reduced 25 in animals fed with WD-Ros compared to animals fed with the control diet. RNA-seq results showed, that 26 especially in animals fed with WD, Ros had a beneficial effect on inflammatory genes. The expression of genes 27 involved in cholesterol biosynthesis, such as Hmgcr, mevalonate kinase (Mvk), squalene epoxidase (Sqle), Cyp51 and stearoyl-Coenzyme A desaturase 2 (Scd2) were affected during both diets. Results show that the 1 anti-inflammatory property of Ros is more pronounced in animals fed with WD. Previously, we have shown 2 that statins have significant anti-inflammatory effects on macrophages [43] . 3 Trib genes are highly conserved genes, which regulate inflammatory signaling pathways through Mapk and 4
Pi3k pathways [29] . Trib family members are differentially expressed in various tissues but exact mechanisms 5 and contribution to inflammatory diseases are not fully understood [29] . It has been shown that Trib3 plays an 6 important role in glucose and lipid metabolism in the liver by inhibiting Akt/protein kinase B [44]. On the 7 contrary, Weismann et al. [45] showed that Trib3 affects lipid metabolism in the liver via PPAR-γ mechanism 8 independent of PI3K. We could show for the first time that Trib genes are affected by Ros treatment in mice 9 lacking the Ldlr gene. In our study the protein levels of Trib2 and Trib3 were downregulated in animals treated 10 with WD-Ros, while Ros treatment did not affect the expression of these proteins in mice fed with RCD. We 11 could not see any changes in downstream signaling pathways, such as phosphorylation of Akt, mTOR or 12 Erk1/2 apart from a slight but significant increase in pmTOR in animals treated with WD-Ros. We also 13 identified Plins to be differentially regulated by statin treatment. We saw a significant downregulation of Plin4 14 RNA levels by Ros in animals fed with WD. 15
In conclusion, we show that Ros acts at the transcriptional level specifically in the liver on lipid and 16 inflammatory pathways without affecting glucose metabolism or cardiac performance. We could also show 17 that in LDLR -/-ApoB 100/100 mice, total cholesterol and liver steatosis could be reduced with Ros treatment. Plin4 18 and Trib2/3 likely play important roles as molecular mediators in the liver after Ros treatment. 
